MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Becton Dickinson and Co

Отворен

СекторЗдравеопазване

203.48 0.18

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

201.79

Максимум

204.89

Ключови измерители

By Trading Economics

Приходи

-118M

303M

Продажби

-272M

5.2B

P/E

Средно за сектора

33.099

57.333

EPS

3.43

Дивидентна доходност

2

Марж на печалбата

5.863

Служители

70,000

EBITDA

-1.3B

453M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+31.64% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.00%

2.63%

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-15B

56B

Предишно отваряне

203.3

Предишно затваряне

203.48

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Becton Dickinson and Co Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.02.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7.11.2024 г., 12:59 ч. UTC

Печалби

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7.11.2024 г., 12:56 ч. UTC

Печалби

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1.08.2024 г., 11:08 ч. UTC

Печалби

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3.06.2024 г., 11:18 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

5.02.2025 г., 21:56 ч. UTC

Печалби

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5.02.2025 г., 21:54 ч. UTC

Печалби

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5.02.2025 г., 21:54 ч. UTC

Печалби

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5.02.2025 г., 21:53 ч. UTC

Печалби

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5.02.2025 г., 21:30 ч. UTC

Печалби

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5.02.2025 г., 21:30 ч. UTC

Печалби

Becton Dickinson 1Q Rev $5.2B >BDX

5.02.2025 г., 21:30 ч. UTC

Печалби

Becton Dickinson 1Q Net $303M >BDX

5.02.2025 г., 21:30 ч. UTC

Печалби

Becton Dickinson 1Q EPS $1.04 >BDX

7.11.2024 г., 11:36 ч. UTC

Печалби

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7.11.2024 г., 11:35 ч. UTC

Печалби

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7.11.2024 г., 11:30 ч. UTC

Печалби

Becton Dickinson 4Q EPS $1.45 >BDX

7.11.2024 г., 11:30 ч. UTC

Печалби

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7.11.2024 г., 11:30 ч. UTC

Печалби

Becton Dickinson 4Q Rev $5.4B >BDX

7.11.2024 г., 11:30 ч. UTC

Печалби

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

1.08.2024 г., 10:37 ч. UTC

Печалби

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1.08.2024 г., 10:35 ч. UTC

Печалби

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1.08.2024 г., 10:35 ч. UTC

Печалби

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q EPS $1.68 >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Net $487M >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1.08.2024 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Rev $5B >BDX

4.06.2024 г., 17:26 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3.06.2024 г., 15:30 ч. UTC

Горещи акции

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3.06.2024 г., 13:26 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3.06.2024 г., 12:25 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Сравнение с други в отрасъла

Ценова промяна

Becton Dickinson and Co Прогноза

Ценова цел

By TipRanks

31.64% нагоре

12-месечна прогноза

Среден 269.13 USD  31.64%

Висок 280 USD

Нисък 260 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Becton Dickinson and Co през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

8

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

199.12 / 207.26Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.